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Purpose: To determine the amount of glycosaminoglycans (GAGs) in tears of patients with 
diabetic retinopathy (DR) and to compare it with normal subjects.
Methods: 38 patients with DR and 24 normal volunteers were included. Thirty subjects suf-
fered from background diabetic retinopathy (BDR) and 8 from proliferate diabetic retinopathy 
(PDR). For the GAGs assay, the uronic carbazole reaction was used.
Results: The mean concentration of GAGs was signiﬁ  cantly higher in patients with DR than 
in normal subjects. The GAGs concentration in patients with BDR or PDR was signiﬁ  cantly 
higher than in normal subjects.
Conclusion: The measurement of GAGs in tears of diabetic patients could be a tool in order 
to assess the stability or not of the disease.
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Introduction
Glycosaminoglycans (GAGs) are linear heteropolysaccharides possessing a charac-
teristic disaccharide repeated sequence. They are ubiquitously found in extracellular 
matrix or in cell surfaces and in intracellular compartment of mast cells. After syn-
thesis into core proteins in Golgi apparatus within the ﬁ  broblasts and related cells. 
The abundant majority of GAGs is released into the extracellular matrix where they 
are bound to structural proteins to form proteoglycans. Free GAG chains are encoun-
tered in considerable amounts in the blood from where they are renally eliminated 
(Poulsen 1986).
The tears, which cover the corneal surface, have functions such as the prevention 
of dryness or infection of the cornea (Mishima 1966). It has been reported that the 
mycoid layer, existing as the lowest layer of tears and playing an important role in 
maintaining the tear ﬁ  lm on the corneal surface, contains some kind of GAGs (Iwata 
and Kabasawa 1971). However, details about the concentration of, composition, and 
function of GAGs in tears are not clear.
Diabetes mellitus and other autoimmune endocrine diseases affect the metabolism 
of GAGs (Hansen et al 1996, 1997). These changes of GAGs metabolism may play 
an important role in the development of diabetic complications and retinal microan-
giopathy (Gambero et al 1989).
The purpose of the present study is to determine the amount of GAGs in tears of 
patients with diabetic retinopathy (DR) and to compare it with normal subjects.
Materials and methods
Thirty eight diabetic patients of either sex (18 male, 20 female) presenting DR were 
included in our study. Twelve of them suffered from Type 1 diabetes mellitus and 
the remaining 26 patients from Type 2 diabetes mellitus. Thirty of them presented 
background diabetic retinopathy (BDR). Their mean age was 54.78 (SD 8.9) years. Clinical Ophthalmology 2008:2(3) 582
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Eight diabetic patients suffered from proliferative diabetic 
retinopathy (PDR). Their mean age was 53.89 (SD 4.3). 
Diabetic patients with uncontrolled diabetes mellitus (HbA1c 
11.4%), albuminuria greater than 14 mg/dl/24 hrs and 
pathological blood pressure were excluded from our study. 
Control subjects were 24 volunteers (12 male, 12 female), 
ophthalmologically normal with no ocular or systemic 
symptoms. Complete clinical examination was performed 
in order to exclude any cardiovascular or metabolic disease. 
All laboratory data were found within the normal range. The 
mean age was 66.65 (SD 8.9) years (Table 1).
Each individual included in our study underwent complete 
ophthalmologic examination including ﬂ  uorescein angiogra-
phy. DR was assessed by fundus examination and ﬂ  uorescein 
angiographic ﬁ  ndings. Retinopathy was graded as present or 
not regardless of the severity of retinal alterations.
All the experiments in this study followed the tenets 
of Declaration of Helsinki. After informed consent was 
obtained, tear samples were collected from both eyes of each 
subject included by placing for a period of 1 minute in the 
lower fornix of the eye 2 circular pieces of 3 mm chromatog-
raphy paper of a diameter of 7 mm. Approximately 250 μl 
of tears were collected from each subject. No anesthetic was 
used. Immediately after, the specimen collection papers were 
placed in sterilized plastic bags and stored.
For the elution of tear specimens, these were placed in 
5 ml polypropylene tubes. The GAGs were eluted by adding 
1 ml of distilled water and gently rocked the sample for 
20 minutes. The eluate was used for GAG assay and protein 
estimation.
GAGs were extracted from the tear samples by 
precipitation using CPC 1% in 0.3% NaCl. Precipitates were 
repeatedly treated with NaCl 2 M and absolute ethanol.
For the GAGs assay, the uronic carbazole reaction was used 
as described by Bitter and Muir (1962). GAGs concentration 
was expressed as uronic acid value μg/ml·mg of protein.
Statistical analysis was performed by using SPSS 10.00 
for Windows (SPSS Inc., Chicago, IL). The one-way 
analysis of variance (ANOVA) and two-tailed independent 
samples were used to analyze the statistical signiﬁ  cance of 
differences between GAGs levels in tear samples of diabetic 
patients and normal individuals. p  0.05 was considered to 
indicate signiﬁ  cance.
Results
Analysis of tears from the diabetic patients shows that the 
mean GAGs concentration is equal to (310.115 ± 12.6 μg/ml 
[mean ± SEM]). Analysis of tears from the Control group reveals 
a mean GAGs concentration equal to (232.3 ± 22.3 μg/ml 
[mean ± SEM]). Statistical analysis was performed which 
shows that the GAGs concentration in tears of diabetic patients 
is signiﬁ  cantly higher than in control subjects (p = 0.002) 
(Table 2).
To further analyze the increase of GAGs in tears of dia-
betic patients, we compared the amount of GAGs in tears 
between Type 1 (insulin-dependent) diabetic patients and 
Type 2 (noninsulin-dependent) diabetic patients. The mean 
GAGs concentration in Type 2 patients is equal to (331.3 ± 
14.2 μg/ml [mean ± SEM]. The mean GAGs concentration 
in Type 1 patients is equal to (273.27 ± 20 μg/ml [mean ± 
SEM]). Statistical analysis was performed which shows that 
the GAGs concentration in tears from the Type II diabetic 
subjects was signiﬁ  cantly greater than the Type I subjects 
(p = 0.019) (Table 3).
To further analyze the increase of GAGs in tears of 
diabetic patients presenting signs of DR, we compared 
the amount of GAGs in tears between patients presenting 
BDR or PDR and the control subjects. The mean GAGs 
concentration in patients with BDR is equal to (305.17 ± 
15.2 μg/ml [mean ± SEM]). The mean GAGs concentra-
tion in patients with PDR is equal to (327.72 ± 27.6 μg/ml 
[mean ± SEM]). Statistical analysis of the results reveals 
Table 1 Patients involved in the study
Group BDR  PDR  Normal
Number of subjects  30  8  24
Gender (male/female)  16/14  4/4  12/12
Mean age (years ± SD)  54.78 ± 4.6  53.89 ± 4.3  66.65 ± 8.9
Abbreviations: BDR, background diabetic retinopathy; PDR, proliferate diabetic 
retinopathy; SD, standard deviation.
Table 2 Mean concentration of GAGs (uronic acid value μg/ml·  mg 
of protein) in tear samples from the diabetic patients and the 
control group
Group (number of patients)  Mean GAGs  SEM
Diabetic patients (n = 38)  310.115  12.6
Control group (n = 24)  232.3  22.3
Abbreviations: GAGs, glycosaminoglycans; SEM, standard error of mean.
Table 3 Mean concentration of GAGs in tear samples of the 
diabetic patients
Group (number of patients)  Mean GAGs  SEM
Type 1 (n = 12)  273.27  20
Type 2 (n = 26)  331.3  14.2
Abbreviations: GAGs, glycosaminoglycans; SEM, standard error of mean.Clinical Ophthalmology 2008:2(3) 583
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that GAGs concentration in tears of patients with BDR was 
signiﬁ  cantly greater than the Control group (p = 0.012) 
(Table 4, Figure 1). Furthermore, GAGs concentration in 
tears of patients with PDR was signiﬁ  cantly greater than the 
Control group (p = 0.034) (Table 4, Figure 2).
Moreover, we compared the BDR group with the PDR 
in order to see if a correlation between the GAGs concentra-
tion in tears and the evolution of DR towards the BDR or the 
PDR type is observed. The mean concentration of GAGs in 
patients with BDR is lower than those presenting PDR, but 
the difference is not statistically signiﬁ  cant (p = 0.489).
Discussion
The most abundant heteropolysaccharides in the body are 
the GAGs. They are located primarily on the surface of 
cells or in the extracellular matrix. They perform numerous 
vital functions within the body, some of which still remain 
to be studied. The origin of blood serum GAGs is not fully 
elucidated, however it is believed that serum GAGs level 
reﬂ  ects active metabolic processes taking place at the tissue 
level (Ceriello et al 1983). Studies on the serum GAGs in 
diabetic patients showed a decrease in chondroitin-4 and an 
increase in Hyaluronic acid concentrations (Malathy and 
Kurup 1973). Later studies demonstrated that in diabetic 
patients total serum GAGs concentration was increased 
(Kozma et al 1996).
The existence of GAGs in tears has been suggested using 
a histochemical technique but their origin remains unknown. 
It was suggested that tears from lacrimal gland contain CD44, 
chondroitin sulfate and keratane sulfate (Yoshida et al 1996). 
Also hyaluronan (HA) and chondroitin sulfate exist in the 
tears of normal rabbit eyes. It is interesting that the increased 
amount of HA concentration in tears signiﬁ  cantly correlated 
with the healing rate of the corneal epithelium (Miyauchi 
et al 1992).
Our results showed that in diabetic patients, the GAGs 
concentration in tears is signiﬁ  cantly greater than in the 
normal subjects, especially in the patients presenting BDR. 
Previous studies on urinary GAGs and diabetic microangi-
opathy showed a remarkably higher GAG urinary excretion 
in diabetic patients with microangiopathy compared to those 
without angiopathy and a close relationship between the renal 
GAG excretion and the presence of microangiopathy in Type 
1 diabetic patients (Kahaly et al 1997). The enhanced urinary 
excretion is possibly explained by pathological changes 
related with distortion of the charge selective barrier and 
Figure 1 Graph showing the mean concentration of GAGs in tears of patients with BDR and normal controls (p  0.05).
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Table 4 Mean concentration of GAGs in tear samples of diabetic 
patients according to the type of the diabetic retinopathy
Group (number of patients)  Mean GAGs  SEM
BDR (n = 30)  305.17  15.2
PDR (n = 8)  327.72  27.6
Abbreviations: BDR, backgr ound diabetic retinopathy; GAGs, glycosaminoglycans; 
PDR, proliferate diabetic retinopathy; SEM, standard error of mean.Clinical Ophthalmology 2008:2(3) 584
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increase permeability of the glomerular basement membrane 
(Deckert et al 1993). In other words, the high urinary GAG 
concentration might be a marker of glomerular involve-
ment in diabetes mellitus. In the same context, according to 
our results, the high tear ﬂ  uid excretion of GAGs may be a 
marker of lacrimal gland involvement in diabetes mellitus. 
However the exact origin of these GAGs based on the data in 
this study is difﬁ  cult to be identiﬁ  ed, but the lacrimal gland 
can be listed as possible origin.
Our results revealed that the GAGs concentration in Type 
2 diabetic patients is signiﬁ  cantly higher than in Type 1. This 
result is in agreement with other studies which showed that 
the total serum GAGs concentration is increased (Kozma 
et al 1996), particularly in patients with poor blood glucose 
control. This increase is expected to bear on the altered glu-
cose metabolism in diabetic patients.
The results in this study showed that there is a signiﬁ  cant 
relationship between the increase of tear ﬂ  uid GAG con-
centration and the presence of diabetic retinopathy. If this 
would be an indice of the appearance or not of the disease, 
it is very soon to be conﬁ  rmed. No signiﬁ  cant relationship 
was observed between the amount of GAGs in tears and 
the evolution of the diabetic retinopathy towards the BDR 
or the PDR type. However further studies are required in 
order to establish the exact origin of GAGs in tears and its 
biochemical role in diabetic retinopathy.
References
Bitter T, Muir HM. 1962. A modiﬁ  ed uronic acid carbazole reaction. Annal 
Biochem, 4:330–4.
Ceriello A, Giungliano D, Dello Russo P, et al. 1983. Glycosaminoglycans 
in human diabetes. Diabetes Metabol, 9:32–4.
Deckert T, Kofoed Enevoldsen A, Vidal P, et al. 1993. Size- and charge 
selectivity of glomerular ﬁ  ltration in Type 1 (insulin-dependent) diabetic 
patients with and without albuminuria. Diabetologia, 36:244–51.
Gambero G, Cicerello E, Mastrosimone S, et al. 1989. High urinary excretion 
of glycosaminoglycans; a possible marker of glomerular involvement 
in diabetes. Metabolism, 38:419–20.
Hansen C, Aichner C, Otto E, et al. 1996. Abberant distribution and increased 
urinary glycosaminoglycans excretion in type II diabetes mellitus 
(NIDDM). Exp Clin Endocrinol Diab, 104:145–9.
Hansen C, Irmscher AK, Kuhlemann K, et al. 1997. Insulin-dependent dia-
betes mellitus and Glycosaminoglycans. Horm Metab Res, 27:555–8.
Iwata S, Kabasawa I. 1971. Fractionation and chemical properties of tear 
mucoid. Exp Eye Res, 12:360–7.
Kahaly G, Hansen C, Otto E, et al. 1997. Diabetic microangiopathy 
and urinary glycosaminoglycans. Exp Clin Endocrinol Diabetes, 
105:145–51.
Kozma EM, Olczyk K, Glowacki A, et al. 1996. Glycosaminoglycans of 
human serum and their alterations in diabetes mellitus. Acta Biochim 
Pol, 43:567–74.
Malathy K, Kurup PA. 1973. Levels of glycosaminoglycans in the serum 
of diabetic patients. Indian J Biochem Biophys, 10:132–3.
Mishima S. 1966. Some physiological aspects of the precorneal tear ﬁ  lm. 
Arch Ophthalmol, 73:233–41.
Miyauchi S, Morita M, Kuramoto K, et al. 1992. Glycosaminoglycans in 
thyroid-associated ophthalmopathy. Autoimmunity, 13:81–8.
Poulsen JH. 1986. Urine and tissue glycosaminoglycans and their interrela-
tions. Dan Med Bull, 33:75–96.
Yoshida K, Nitatori Y, Uchiyama Y, 1996. Localisation of glycosamino-
glycans and the CD44 in the human lacrimal gland. Arch Histol Cytol, 
59:505–13.
Figure 2 Graph showing the mean concentration of GAGs in tears of patients with PDR and normal individuals (p  0.05).
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